{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:31:59Z","timestamp":1792675919883,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CCR4 is highly expressed on Th2 cells. CCR4 ligands include CCL22 and CCL17. Chemokine-like factor 1 can also mediate chemotaxis via CCR4. We designed and synthetized novel CCR4 antagonists, which were piperazinyl pyridine derivatives, for disrupting the interaction between three ligands and CCR4. We also determined whether these novel CCR4 antagonists could alleviate allergic asthma in a mouse. For identifying the potent compounds in\n                    <jats:italic>vitro<\/jats:italic>\n                    , we used chemotaxis inhibition and competition binding assays induced by CCL22, CCL17 and one of CKLF1\u2019s C-terminal peptides, C27. We found compound 8a which showed excellent potency in blocking the interaction of CCR4 and its three ligands. For studying the specificity of compounds, we chose chemotaxis inhibition assays with different receptors and ligands. We found compound 8a had excellent receptor specificity and exerted few influence on the interaction of other receptors and their ligands. In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, compound 8a had no obvious cytotoxicity till the higher concentration (16\u2009\u03bcM). For determining the potency of compounds in blocking the interaction of CCR4 in\n                    <jats:italic>vivo<\/jats:italic>\n                    , we used the ovalbumin induced allergic asthma model in mice. Our study demonstrated that CCR4 blockaded by compound 8a effectively attenuated airway hyperresponsiveness, airway eosinophilia and Th2 cytokines.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-11868-9","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T15:54:40Z","timestamp":1509638080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma"],"prefix":"10.1038","volume":"7","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinfang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhai","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"11868_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/nri2870","volume":"10","author":"CM Lloyd","year":"2010","unstructured":"Lloyd, C. M. & Hessel, E. M. Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol 10, 838\u201348 (2010).","journal-title":"Nat Rev Immunol"},{"key":"11868_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1517\/13543784.2013.732997","volume":"22","author":"PM Hansbro","year":"2013","unstructured":"Hansbro, P. M. et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs 22, 49\u201369 (2013).","journal-title":"Expert Opin Investig Drugs"},{"key":"11868_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaci.2005.03.052","volume":"116","author":"AJ Morgan","year":"2005","unstructured":"Morgan, A. J. et al. IL-4-expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR 3 and CCR 4. J Allergy Clin Immunol 116, 594\u2013600 (2005).","journal-title":"J Allergy Clin Immunol"},{"key":"11868_CR4","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.4049\/jimmunol.0901342","volume":"184","author":"P Vijayanand","year":"2010","unstructured":"Vijayanand, P. et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 184, 4568\u201374 (2010).","journal-title":"J Immunol"},{"key":"11868_CR5","doi-asserted-by":"crossref","unstructured":"Larche, M., Robinson, D.S. & Kay, A.B. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 111, 450-63; quiz 464 (2003).","DOI":"10.1067\/mai.2003.169"},{"key":"11868_CR6","doi-asserted-by":"publisher","first-page":"15036","DOI":"10.1074\/jbc.272.23.15036","volume":"272","author":"T Imai","year":"1997","unstructured":"Imai, T. et al. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 272, 15036\u201342 (1997).","journal-title":"J Biol Chem"},{"key":"11868_CR7","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1074\/jbc.273.3.1764","volume":"273","author":"T Imai","year":"1998","unstructured":"Imai, T. et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 273, 1764\u20138 (1998).","journal-title":"J Biol Chem"},{"key":"11868_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaci.2003.08.012","volume":"112","author":"BS Bochner","year":"2003","unstructured":"Bochner, B. S., Hudson, S. A., Xiao, H. Q. & Liu, M. C. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. J Allergy Clin Immunol 112, 930\u20134 (2003).","journal-title":"J Allergy Clin Immunol"},{"key":"11868_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1183\/09031936.04.00102504","volume":"23","author":"C Pilette","year":"2004","unstructured":"Pilette, C., Francis, J. N., Till, S. J. & Durham, S. R. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur Respir J 23, 876\u201384 (2004).","journal-title":"Eur Respir J"},{"key":"11868_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4049\/jimmunol.163.1.403","volume":"163","author":"JA Gonzalo","year":"1999","unstructured":"Gonzalo, J. A. et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol 163, 403\u201311 (1999).","journal-title":"J Immunol"},{"key":"11868_CR11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.4049\/jimmunol.166.3.2055","volume":"166","author":"S Kawasaki","year":"2001","unstructured":"Kawasaki, S. et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J Immunol 166, 2055\u201362 (2001).","journal-title":"J Immunol"},{"key":"11868_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.lfs.2005.05.070","volume":"78","author":"Y Wang","year":"2006","unstructured":"Wang, Y. et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci 78, 614\u201321 (2006).","journal-title":"Life Sci"},{"key":"11868_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1042\/bj3570127","volume":"357","author":"W Han","year":"2001","unstructured":"Han, W. et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 357, 127\u201335 (2001).","journal-title":"Biochem J"},{"key":"11868_CR14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1021\/jm901652p","volume":"53","author":"G Li","year":"2010","unstructured":"Li, G. et al. Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice. J Med Chem 53, 1741\u201354 (2010).","journal-title":"J Med Chem"},{"key":"11868_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.biocel.2007.10.028","volume":"40","author":"Y Wang","year":"2008","unstructured":"Wang, Y. et al. Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4. Int J Biochem Cell Biol 40, 909\u201319 (2008).","journal-title":"Int J Biochem Cell Biol"},{"key":"11868_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1398-9995.2010.02478.x","volume":"66","author":"L Tian","year":"2011","unstructured":"Tian, L. et al. The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma. Allergy 66, 287\u201397 (2011).","journal-title":"Allergy"},{"key":"11868_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bmcl.2006.10.091","volume":"17","author":"AV Purandare","year":"2007","unstructured":"Purandare, A. V. et al. Core exploration in optimization of chemokine receptor CCR4 antagonists. Bioorg Med Chem Lett 17, 679\u201382 (2007).","journal-title":"Bioorg Med Chem Lett"},{"key":"11868_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bmcl.2005.09.022","volume":"16","author":"AV Purandare","year":"2006","unstructured":"Purandare, A. V. et al. Optimization of CCR4 antagonists: side-chain exploration. Bioorg Med Chem Lett 16, 204\u20137 (2006).","journal-title":"Bioorg Med Chem Lett"},{"key":"11868_CR19","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1016\/j.bmcl.2005.02.084","volume":"15","author":"AV Purandare","year":"2005","unstructured":"Purandare, A. V. et al. Identification of chemokine receptor CCR4 antagonist. Bioorg Med Chem Lett 15, 2669\u201372 (2005).","journal-title":"Bioorg Med Chem Lett"},{"key":"11868_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bmc.2008.11.020","volume":"17","author":"K Yokoyama","year":"2009","unstructured":"Yokoyama, K. et al. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg Med Chem 17, 64\u201373 (2009).","journal-title":"Bioorg Med Chem"},{"key":"11868_CR21","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.bmcl.2007.03.030","volume":"17","author":"DF Burdi","year":"2007","unstructured":"Burdi, D. F. et al. Small molecule antagonists of the CC chemokine receptor 4 (CCR4). Bioorg Med Chem Lett 17, 3141\u20135 (2007).","journal-title":"Bioorg Med Chem Lett"},{"key":"11868_CR22","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.bmcl.2006.01.126","volume":"16","author":"X Wang","year":"2006","unstructured":"Wang, X. et al. Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett 16, 2800\u20133 (2006).","journal-title":"Bioorg Med Chem Lett"},{"key":"11868_CR23","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1016\/j.bmcl.2004.09.001","volume":"14","author":"B Newhouse","year":"2004","unstructured":"Newhouse, B. et al. Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists. Bioorg Med Chem Lett 14, 5537\u201342 (2004).","journal-title":"Bioorg Med Chem Lett"},{"key":"11868_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1747-0285.2007.00551.x","volume":"70","author":"CF Kuhn","year":"2007","unstructured":"Kuhn, C. F. et al. Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists. Chem Biol Drug Des 70, 268\u201372 (2007).","journal-title":"Chem Biol Drug Des"},{"key":"11868_CR25","doi-asserted-by":"publisher","first-page":"9961","DOI":"10.3390\/molecules17089961","volume":"17","author":"H Gong","year":"2012","unstructured":"Gong, H. et al. Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists. Molecules 17, 9961\u201370 (2012).","journal-title":"Molecules"},{"key":"11868_CR26","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1084\/jem.167.4.1406","volume":"167","author":"D Vercelli","year":"1988","unstructured":"Vercelli, D. et al. Human recombinant interleukin 4 induces Fc epsilon R2\/CD23 on normal human monocytes. J Exp Med 167, 1406\u201316 (1988).","journal-title":"J Exp Med"},{"key":"11868_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1172\/JCI12655","volume":"107","author":"P Panina-Bordignon","year":"2001","unstructured":"Panina-Bordignon, P. et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 107, 1357\u201364 (2001).","journal-title":"J Clin Invest"},{"key":"11868_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1084\/jem.191.2.265","volume":"191","author":"CM Lloyd","year":"2000","unstructured":"Lloyd, C. M. et al. CC chemokine receptor (CCR)3\/eotaxin is followed by CCR4\/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J Exp Med 191, 265\u201374 (2000).","journal-title":"J Exp Med"},{"key":"11868_CR29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1398-9995.2010.02327.x","volume":"65","author":"G Banfield","year":"2010","unstructured":"Banfield, G. et al. CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses. Allergy 65, 1126\u201333 (2010).","journal-title":"Allergy"},{"key":"11868_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1096\/fj.05-5045com","volume":"20","author":"KS Lee","year":"2006","unstructured":"Lee, K. S., Lee, H. K., Hayflick, J. S., Lee, Y. C. & Puri, K. D. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 20, 455\u201365 (2006).","journal-title":"FASEB J"}],"updated-by":[{"DOI":"10.1038\/s41598-018-23185-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11868-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:22:58Z","timestamp":1719544978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11868-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11868"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11868-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]},"assertion":[{"value":"26 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15038"}}